Physical Address
Indirizzo: Via Mario Greco 60, Buttigliera Alta, 10090, Torino, Italy
The Algerian leader in the pharmaceutical industry Saidal has signed a memorandum of understanding with the American biopharmaceutical group Abbvie, represented in Algeria by the operating company Promdex. This signature marks “the launch of strategic cooperation” between the two parties, the Algerian group said in a press release.
The signature ceremony took place at the Ministry of the Pharmaceutical Industry, in the presence of the Minister of the Ouacim Kouidri sector, the Director General of the Saidal Group, Nabila Benygzer, the Director General of Laboratories Abbvie in North Africa, Ms. Makhloufi Amal, of the Abbvie Vice-President of the Mear Region (Middle East, Africa and Eurasia) Aboubakr as well as executives of the two entities.
Abbvie will accompany Saidal In the training and development of staff skills of the Equival Bioceter Bioéquivalence Center. This cooperation will initially relate to the implementation of certifying training programs, workshops and transfer of know-how dedicated to bioequivalence studies and clinical research. It also opens the way to a broader strategic partnership which will concern other areas, such as good practices of pharmaceutical production.
In addition, and still in the health sector, Minister Abdelhak Saihi And Ouaci Kouidri climbed the ranks to obtain international maturity certification 3 (ML3) of the World Health Organization (WHO), a strategic label that will open the doors to the world markets, according to a joint press release from the two ministries made public yesterday.
Gathered around the same table, they drew a roadmap to propel the Algerian drug outside its borders. The challenge is high: it involves raising the sector to international standards and establishing flawless credibility in the face of market giants.
Kouidri said, on this occasion, that “this certification will open the way to export and considerably simplify the registration of Algerian drugs abroad”. Convinced that Algeria today has the means to play in the big leagues, he stressed the imperative to secure the sector to the most demanding standards.
For his part, the Minister of Health insisted on the total mobilization of his department in order to achieve this strategic objective, declaring, with the same determination, that “we make all the means available to obtain this classification, especially in the face of the high African demand for our pharmaceutical products”. Recalling that Algeria has a production potential capable of meeting regional needs “, it underlined the strategic asset of the African market, in which Algeria aspires to impose itself as a major supplier.
Beyond the simple label, the objective of synergy of the two departments is to obtain international recognition which would place the national pharmaceutical industry in a position of strength, capable of competing and exporting massively. In a context where Africa has become an economic battlefield for the great powers, Algeria thus intends to assert its know-how and transform its health sovereignty into a lever of economic power.